Desonide (generic name), a topical steroidal skin-cream, or ointment, used to treat eczema and dermatitis in children, and also used on the sensitive area of the eyelids has seen an enormous recent rise in cost to the consumer, may be due to collusion among three manufacturers. The plaintiff, an employee health fund, in the federal anti-trust class action, claims the three major manufacturers met in 2013 and decided to fix prices, placing the drug out of reach of many American patients.
According to Wikipedia, “Desonide was first introduced in the United States under the trade name Tridesilon by Dome Laboratories in 1970.
One doctor raised the issue of sudden price fluctuation on-line at Dermatology News, stating, “But lately I’ve been getting complaints from patients about the high cost of desonide. My first reaction to these was, “How on earth is that possible?”
This price-fixing allegation, filed by representatives of the Sergeants Benevolent Association Health & Welfare Fund (SBA Fund), seeks restitution and treble damages.
*****A VITAL NOTE FROM THE PIRL TEAM: As we report on any medical product/medication case - NEVER STOP OR ALTER A MEDICAL PROGRAM OR COURSE OF MEDICATION WITHOUT CONSULTING YOUR(S) OR A PHYSICIAN.*****